Amicus Therapeutics, Inc. (FOLD)
$11.025
Rating:
Recommendation:
Buy
Symbol | FOLD |
---|---|
Price | $11.025 |
Beta | 0.865 |
Volume Avg. | 2.44M |
Market Cap | 3.233B |
Shares () | - |
52 Week Range | 9.7-14.1 |
1y Target Est | - |
DCF Unlevered | FOLD DCF -> | |
---|---|---|
DCF Levered | FOLD LDCF -> | |
ROE | -147.61% | Strong Sell |
ROA | -22.72% | Sell |
Operating Margin | - | |
Debt / Equity | 340.96% | Strong Buy |
P/E | -18.69 | Strong Sell |
P/B | 24.47 | Strong Buy |
Latest FOLD news
About
Download (Excel)Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.